

# Tony P George

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7968946/publications.pdf>

Version: 2024-02-01

206  
papers

10,305  
citations

31976

53  
h-index

39675

94  
g-index

206  
all docs

206  
docs citations

206  
times ranked

8722  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined effect of alcohol and cannabis on simulated driving. <i>Psychopharmacology</i> , 2022, 239, 1263-1277.	3.1	15
2	Why Integrating Medications and Psychosocial Interventions is Important to Successfully Address the Opioid Crisis in Canada. <i>Canadian Journal of Psychiatry</i> , 2022, 67, 176-178.	1.9	8
3	Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia. <i>NPJ Schizophrenia</i> , 2022, 8, 2.	3.6	9
4	Neuromodulation to Treat Substance Use Disorders in People With Schizophrenia and Other Psychoses: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2022, 13, 793938.	2.6	6
5	Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 719-742.	2.6	40
6	Dose-dependent effects of Varenicline on tobacco craving and withdrawal in tobacco smokers with and without schizophrenia. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109412.	3.2	3
7	Separate and combined effects of alcohol and cannabis on mood, subjective experience, cognition and psychomotor performance: A randomized trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 118, 110570.	4.8	6
8	P24. Effects of Cannabis Legalization in Canada on Daily Cannabis Use in Mental Health Disorders. <i>Biological Psychiatry</i> , 2022, 91, S97.	1.3	0
9	Effects of 28 days of cannabis abstinence on cognition in major depressive disorder: A pilot study. <i>American Journal on Addictions</i> , 2022, 31, 454-462.	1.4	4
10	Non-Invasive Neuromodulation of Dorsolateral Prefrontal Cortex to Reduce Craving in Alcohol Use Disorder: A Meta-Analysis. , 2022, , 100076.		3
11	Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent. <i>Molecular Psychiatry</i> , 2021, 26, 2212-2223.	7.9	45
12	Comparing the Rate of Nicotine Metabolism Among Smokers With Current or Past Major Depressive Disorder. <i>American Journal on Addictions</i> , 2021, 30, 382-388.	1.4	0
13	Randomized trial of a brief peer support intervention for individuals with schizophrenia transitioning from hospital to community. <i>Schizophrenia Research</i> , 2021, 231, 214-220.	2.0	7
14	Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies. <i>Drug and Alcohol Dependence</i> , 2021, 223, 108708.	3.2	7
15	A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 535-547.	2.1	13
16	Sex differences in the acute pharmacological and subjective effects of smoked cannabis combined with alcohol in young adults.. <i>Psychology of Addictive Behaviors</i> , 2021, 35, 536-552.	2.1	13
17	Effects of Cannabis Use on Psychotic and Mood Symptoms: A Systematic Review. <i>Canadian Journal of Addiction</i> , 2021, 12, 10-21.	0.4	5
18	Concurrent Disorders Management in Psychiatric Care: Opportunities and Challenges. <i>Canadian Journal of Addiction</i> , 2021, 12, 7-9.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Substance Use Psychosis. , 2021, , 107-124.		0
20	The Behavioral Sequelae of Cannabis Use in Healthy People: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 630247.	2.6	24
21	Patterns of lapses and recoveries during a quit attempt using varenicline and behavioral counseling among smokers with and without HIV.. <i>Psychology of Addictive Behaviors</i> , 2021, 35, 788-796.	2.1	4
22	Nicotine and Tobacco. , 2021, , 197-214.		0
23	To Incarcerate or Not to Incarcerate: Is That the Right Question for Drug Addiction?. <i>Canadian Journal of Psychiatry</i> , 2021, , 070674372110630.	1.9	0
24	Discrete Roles for Impulsivity and Compulsivity in Gambling Disorder. <i>Frontiers in Psychiatry</i> , 2021, 12, 789940.	2.6	2
25	Cannabis and Cannabinoids in Mood and Anxiety Disorders: Impact on Illness Onset and Course, and Assessment of Therapeutic Potential. <i>American Journal on Addictions</i> , 2020, 29, 9-26.	1.4	41
26	Acute and residual mood and cognitive performance of young adults following smoked cannabis. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 194, 172937.	2.9	18
27	Neuropsychological and Neurophysiological Measures Associated With Changes in Cannabis Use and rTMS Treatment Response in Schizophrenia. <i>Biological Psychiatry</i> , 2020, 87, S425.	1.3	1
28	Pharmacotherapy for smoking cessation in schizophrenia: a systematic review. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 581-590.	1.8	12
29	Evaluation of nicotine patch adherence measurement using self-report and saliva cotinine among abstainers in a smoking cessation trial. <i>Drug and Alcohol Dependence</i> , 2020, 210, 107967.	3.2	1
30	Cannabis use, cognitive performance, and symptoms of attention deficit/hyperactivity disorder in community adults.. <i>Experimental and Clinical Psychopharmacology</i> , 2020, 28, 638-648.	1.8	8
31	Effects of Extended Cannabis Abstinence in Major Depressive Disorder. <i>Canadian Journal of Addiction</i> , 2020, 11, 33-41.	0.4	8
32	Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1398-1414.	2.1	4
33	Exposure to attachment figure cue reduces cigarette craving.. <i>Experimental and Clinical Psychopharmacology</i> , 2020, 28, 81-86.	1.8	2
34	Effects of Tobacco Smoking Status on Verbal Learning and Memory in Patients With Schizophrenia and Non-ψPsychiatric Controls. <i>American Journal on Addictions</i> , 2019, 28, 503-511.	1.4	4
35	Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: A consensus paper on the present state of the science and the road ahead. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 104, 118-140.	6.1	198
36	Acute and residual effects of smoked cannabis: Impact on driving speed and lateral control, heart rate, and self-reported drug effects. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107641.	3.2	44

#	ARTICLE	IF	CITATIONS
37	Therapeutic cannabis use in 2018: where do we stand?. <i>Lancet Psychiatry</i> , 2019, 6, 88-89.	7.4	5
38	Pharmacotherapies for co-occurring substance use and bipolar disorders: A systematic review. <i>Bipolar Disorders</i> , 2019, 21, 595-610.	1.9	17
39	Effects of the Nicotinic Partial Agonist Varenicline on Smoking Lapse Behaviour in Schizophrenia. <i>Canadian Journal of Addiction</i> , 2019, 10, 27-35.	0.4	1
40	Differences in the rate of nicotine metabolism among smokers with and without HIV. <i>Aids</i> , 2019, 33, 1083-1088.	2.2	36
41	FAAH inhibition for treatment of problematic cannabis use. <i>Lancet Psychiatry</i> , 2019, 6, 3-4.	7.4	1
42	Cannabis legalisation in Canada: a crucial trial balloon. <i>Lancet Psychiatry</i> , 2019, 6, 5-6.	7.4	10
43	Cannabis and mental illness: a review. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 107-120.	3.2	153
44	The neurobiology of impulsivity and substance use disorders: implications for treatment. <i>Annals of the New York Academy of Sciences</i> , 2019, 1451, 71-91.	3.8	114
45	Evaluating the temporal relationships between withdrawal symptoms and smoking relapse.. <i>Psychology of Addictive Behaviors</i> , 2019, 33, 105-116.	2.1	45
46	A review of brain stimulation methods to treat substance use disorders. <i>American Journal on Addictions</i> , 2018, 27, 71-91.	1.4	116
47	Using Mismatch Negativity to Investigate the Pathophysiology of Substance Use Disorders and Comorbid Psychosis. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 226-237.	1.7	8
48	Effects of short-term, high-frequency repetitive transcranial magnetic stimulation to bilateral dorsolateral prefrontal cortex on smoking behavior and cognition in patients with schizophrenia and non-psychiatric controls. <i>Schizophrenia Research</i> , 2018, 197, 441-443.	2.0	27
49	Cannabis Legalization and Psychiatric Disorders: Caveat <i>â€œHemp-torâ€</i> . <i>Canadian Journal of Psychiatry</i> , 2018, 63, 447-450.	1.9	14
50	Changes in tobacco consumption in cannabis dependent patients with schizophrenia versus non-psychiatric controls during 28-days of cannabis abstinence. <i>Drug and Alcohol Dependence</i> , 2018, 185, 181-188.	3.2	10
51	Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. <i>Schizophrenia Research</i> , 2018, 194, 55-61.	2.0	18
52	Effects of varenicline on cognitive function in non-smokers with schizophrenia. <i>Schizophrenia Research</i> , 2018, 197, 562-563.	2.0	6
53	Reduced Short-Latency Afferent Inhibition in Prefrontal but not Motor Cortex and Its Association With Executive Function in Schizophrenia: A Combined TMS-EEG Study. <i>Schizophrenia Bulletin</i> , 2018, 44, 193-202.	4.3	29
54	A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls. <i>Schizophrenia Research</i> , 2018, 194, 47-54.	2.0	10

#	ARTICLE	IF	CITATIONS
55	Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. <i>Addiction</i> , 2018, 113, 509-523.	3.3	45
56	Neurobiological Determinants of Tobacco Smoking in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018, 9, 672.	2.6	34
57	Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPAR $\alpha$ agonist) in smokers. <i>PLoS ONE</i> , 2018, 13, e0201512.	2.5	12
58	A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 882-891.	2.5	13
59	Cannabis and Mood Disorders. <i>Current Addiction Reports</i> , 2018, 5, 336-345.	3.4	30
60	Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: Impact on pharmacogenetic trial outcomes. <i>Drug and Alcohol Dependence</i> , 2018, 190, 72-81.	3.2	11
61	Outcomes of an integrated care pathway for concurrent major depressive and alcohol use disorders: a multisite prospective cohort study. <i>BMC Psychiatry</i> , 2018, 18, 189.	2.6	10
62	Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. <i>PLoS ONE</i> , 2018, 13, e0190768.	2.5	88
63	Impaired theta-gamma coupling during working memory performance in schizophrenia. <i>Schizophrenia Research</i> , 2017, 189, 104-110.	2.0	67
64	Sex differences in the relationships between childhood adversity, attachment anxiety and current smoking. <i>Addiction Research and Theory</i> , 2017, 25, 146-153.	1.9	5
65	Becoming tobacco-free: Changes in staff and patient attitudes and incident reports in a large academic mental health and addictions hospital. <i>American Journal on Addictions</i> , 2017, 26, 183-191.	1.4	14
66	Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls. <i>Neuropsychopharmacology</i> , 2017, 42, 2259-2271.	5.4	28
67	Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment?. <i>Journal of Smoking Cessation</i> , 2017, 12, 63-70.	1.0	23
68	Corticotropin-releasing hormone and dopamine release in healthy individuals. <i>Psychoneuroendocrinology</i> , 2017, 76, 192-196.	2.7	20
69	Management of mood and anxiety disorders in patients receiving opioid agonist therapy: Review and meta-analysis. <i>American Journal on Addictions</i> , 2017, 26, 551-563.	1.4	18
70	Measures and predictors of varenicline adherence in the treatment of nicotine dependence. <i>Addictive Behaviors</i> , 2017, 75, 122-129.	3.0	31
71	176. The Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Smoking Behaviour and Cognition in Smokers with Schizophrenia versus Non-Psychiatric Control Smokers. <i>Biological Psychiatry</i> , 2017, 81, S73.	1.3	0
72	Traits and Biomarkers for Addiction Risk in Schizophrenia. <i>Current Addiction Reports</i> , 2017, 4, 14-24.	3.4	10

#	ARTICLE	IF	CITATIONS
73	Understanding the Link Between Cannabinoids and Psychosis. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 197-199.	4.7	12
74	Differential effects of cannabis dependence on cortical inhibition in patients with schizophrenia and non-psychiatric controls. <i>Brain Stimulation</i> , 2017, 10, 275-282.	1.6	8
75	Integrated care pathway for co-occurring major depressive and alcohol use disorders: Outcomes of the first two years. <i>American Journal on Addictions</i> , 2017, 26, 602-609.	1.4	10
76	Cannabis and psychosis: understanding the smoke signals. <i>Lancet Psychiatry</i> , 2016, 3, 909-910.	7.4	3
77	Effects of varenicline on motor cortical plasticity in non-smokers with schizophrenia. <i>Schizophrenia Research</i> , 2016, 178, 50-55.	2.0	2
78	Does cannabis use moderate smoking cessation outcomes in treatment-seeking tobacco smokers? Analysis from a large multicenter trial. <i>American Journal on Addictions</i> , 2016, 25, 291-296.	1.4	22
79	Cannabis Use and Psychiatric Disorders: Implications for Mental Health and Addiction Treatment. <i>Current Addiction Reports</i> , 2016, 3, 450-462.	3.4	9
80	The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio. <i>Nicotine and Tobacco Research</i> , 2016, 18, 491-495.	2.6	24
81	Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 148, 1-7.	2.9	51
82	Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence. <i>Journal of Addiction Medicine</i> , 2016, 10, 274-279.	2.6	32
83	Integrated Care Pathways for Schizophrenia: A Scoping Review. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2016, 43, 760-767.	2.1	13
84	Deficits in GABAA receptor function and working memory in non-smokers with schizophrenia. <i>Schizophrenia Research</i> , 2016, 171, 125-130.	2.0	14
85	Co-morbid tobacco use disorder and depression: A re-evaluation of smoking cessation therapy in depressed smokers. <i>American Journal on Addictions</i> , 2015, 24, 687-694.	1.4	32
86	Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. <i>PLoS ONE</i> , 2015, 10, e0128109.	2.5	40
87	Minimal evidence that untreated psychosis damages brain structures: A systematic review. <i>Schizophrenia Research</i> , 2015, 162, 222-233.	2.0	35
88	Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2015, 3, 131-138.	10.7	247
89	Measuring Cigarette Smoking-Induced Cortical Dopamine Release: A [11C]FLB-457 PET Study. <i>Neuropsychopharmacology</i> , 2015, 40, 1417-1427.	5.4	43
90	Nicotine Metabolite Ratio (3-Hydroxycotinine/Cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical Implementation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1239-1246.	2.5	65

#	ARTICLE	IF	CITATIONS
91	An Association Between the Use of Hypnotics and Quit Status in the Treatment of Nicotine Dependence With Varenicline in Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 199-200.	1.4	3
92	Circumspectives: The Promise of Ketamine. <i>Neuropsychopharmacology</i> , 2015, 40, 257-258.	5.4	1
93	Dr Chengappa and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 625-626.	2.2	0
94	Pharmacotherapies for nicotine addiction in adults and adolescents. <i>Journal of Pediatric Biochemistry</i> , 2015, 01, 165-174.	0.2	1
95	Training in Substance-Related and Addictive Disorders, Part 1: Overview of Clinical Practice and General Recommendations. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 1-9.	1.9	3
96	Training in Substance-Related and Addictive Disorders, Part 2: Updated Curriculum Guidelines. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 1-12.	1.9	23
97	Known and Novel Sources of Variability in the Nicotine Metabolite Ratio in a Large Sample of Treatment-Seeking Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1773-1782.	2.5	101
98	Neurobiology of Comorbid Substance Use Disorders in Mental Illness: A Closer Look at the Underlying Commonalities between Cannabis and Schizophrenia. <i>Current Addiction Reports</i> , 2014, 1, 261-271.	3.4	4
99	Translating Neurobiology to the Treatment of Dual Diagnosis: The Example of Nicotinic Receptors and Neurocognitive Endophenotypes in Schizophrenia. <i>Current Addiction Reports</i> , 2014, 1, 272-280.	3.4	2
100	Heightened D3 Dopamine Receptor Levels in Cocaine Dependence and Contributions to the Addiction Behavioral Phenotype: A Positron Emission Tomography Study with [11C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2014, 39, 311-318.	5.4	99
101	A review of drug policy in the Golden Crescent: Towards the development of more effective solutions. <i>Asian Journal of Psychiatry</i> , 2014, 12, 31-35.	2.0	4
102	Testing a modification of cognitive adaptation training: Streamlining the model for broader implementation. <i>Schizophrenia Research</i> , 2014, 156, 46-50.	2.0	15
103	The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. <i>Psychopharmacology</i> , 2014, 231, 2515-2523.	3.1	55
104	Treatment of Comorbid Tobacco Addiction in Substance Use and Psychiatric Disorders. <i>Current Addiction Reports</i> , 2014, 1, 61-68.	3.4	6
105	Elevation of Dopamine Induced by Cigarette Smoking: Novel Insights from a [11C]-(+)-PHNO PET Study in Humans. <i>Neuropsychopharmacology</i> , 2014, 39, 415-424.	5.4	54
106	Neurocognitive endophenotypes in schizophrenia: Modulation by nicotinic receptor systems. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 52, 79-85.	4.8	52
107	Relationship between tobacco and cannabis use status in outpatients with schizophrenia. <i>American Journal on Addictions</i> , 2014, 23, 170-175.	1.4	9
108	Deep Repetitive Transcranial Magnetic Stimulation for Smoking Cessation: Is Going Deeper Better?. <i>Biological Psychiatry</i> , 2014, 76, 678-680.	1.3	4



#	ARTICLE	IF	CITATIONS
109	Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. <i>Drug and Alcohol Dependence</i> , 2014, 136, 36-42.	3.2	27
110	Cognitive remediation for individuals with psychosis in a supported education setting: A randomized controlled trial. <i>Schizophrenia Research</i> , 2014, 157, 90-98.	2.0	29
111	Stress-Induced Dopamine Response in Subjects at Clinical High Risk for Schizophrenia with and without Concurrent Cannabis Use. <i>Neuropsychopharmacology</i> , 2014, 39, 1479-1489.	5.4	86
112	The Role of Untreated Psychosis in Neurodegeneration: A Review of Hypothesized Mechanisms of Neurotoxicity in First-Episode Psychosis. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 513-517.	1.9	34
113	Lung Ultrasonography Compared to Computed Tomography Scan in the Detection of Pulmonary Pathology In Noncritically-Ill Medical/Surgical Patients. <i>Chest</i> , 2014, 146, 579A.	0.8	0
114	Brain Stimulation Methods to Treat Tobacco Addiction. <i>Brain Stimulation</i> , 2013, 6, 221-230.	1.6	84
115	Bipolar disorder and co-occurring cannabis use disorders: Characteristics, co-morbidities and clinical correlates. <i>Psychiatry Research</i> , 2013, 209, 459-465.	3.3	96
116	Effect of COMT Val158Met genotype on nicotine withdrawal-related cognitive dysfunction in smokers with and without schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 602-603.	2.0	2
117	Dopamine Response to Psychosocial Stress in Chronic Cannabis Users: A PET Study With [ <sup>11</sup> C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2013, 38, 673-682.	5.4	45
118	Effects of cannabis use status on cognitive function, in males with schizophrenia. <i>Psychiatry Research</i> , 2013, 206, 158-165.	3.3	39
119	Varenicline modulates spatial working memory deficits in smokers with schizophrenia. <i>Schizophrenia Research</i> , 2013, 149, 190-191.	2.0	28
120	Cannabis use and cannabis use disorders among individuals with mental illness. <i>Comprehensive Psychiatry</i> , 2013, 54, 589-598.	3.1	100
121	Effects of Tobacco Smoking on Neuropsychological Function in Schizophrenia in Comparison to Other Psychiatric Disorders and Non-psychiatric Controls. <i>American Journal on Addictions</i> , 2013, 22, 46-53.	1.4	49
122	A Preliminary Feasibility Study of Varenicline for Smoking Cessation in Bipolar Disorder. <i>Journal of Dual Diagnosis</i> , 2012, 8, 131-132.	1.2	35
123	Higher Binding of the Dopamine D <sub>3</sub> Receptor-Preferring Ligand [ <sup>11</sup> C]-(+)-Propyl-Hexahydro-Naphtho-Oxazin in Methamphetamine Polydrug Users: A Positron Emission Tomography Study. <i>Journal of Neuroscience</i> , 2012, 32, 1353-1359.	3.6	152
124	Reproducibility of the Nicotine Metabolite Ratio in Cigarette Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1105-1114.	2.5	96
125	Effects of cigarette smoking status on delay discounting in schizophrenia and healthy controls. <i>Addictive Behaviors</i> , 2012, 37, 67-72.	3.0	56
126	Treatment of Tobacco Dependence in People With Mental Health and Addictive Disorders. <i>Current Psychiatry Reports</i> , 2012, 14, 478-485.	4.5	55



#	ARTICLE	IF	CITATIONS
127	High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. <i>Schizophrenia Research</i> , 2012, 139, 264-266.	2.0	68
128	A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. <i>Annals of the New York Academy of Sciences</i> , 2012, 1248, 89-106.	3.8	86
129	Smoking Cue Reactivity in Adult Smokers with and without Depression: A Pilot Study. <i>American Journal on Addictions</i> , 2012, 21, 136-144.	1.4	22
130	A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Varenicline for Smoking Cessation in Patients With Schizophrenia or Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 654-660.	2.2	148
131	Repetitive transcranial magnetic stimulation and drug addiction. <i>International Review of Psychiatry</i> , 2011, 23, 454-466.	2.8	64
132	Spatial working memory impairments induced by cigarette smoking abstinence are correlated with plasma nicotine levels in schizophrenia. <i>Schizophrenia Research</i> , 2011, 128, 171-172.	2.0	11
133	The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis. <i>Schizophrenia Research</i> , 2011, 128, 111-116.	2.0	121
134	Differences in smoking expectancies in smokers with and without a history of major depression. <i>Addictive Behaviors</i> , 2011, 36, 434-437.	3.0	56
135	Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status. <i>Psychiatry Research</i> , 2011, 188, 320-326.	3.3	71
136	Pharmacogenetics of alcohol, nicotine and drug addiction treatments. <i>Addiction Biology</i> , 2011, 16, 357-376.	2.6	61
137	Impact of a smoke-free policy in a large psychiatric hospital on staff attitudes and patient behavior. <i>General Hospital Psychiatry</i> , 2010, 32, 623-630.	2.4	21
138	A Tobacco Reconceptualization in Psychiatry: Toward the Development of Tobacco-Free Psychiatric Facilities. <i>American Journal on Addictions</i> , 2010, 19, 293-311.	1.4	35
139	Changes in smoking expectancies in abstinent, reducing, and non-abstinent participants during a pharmacological trial for smoking cessation. <i>Nicotine and Tobacco Research</i> , 2010, 12, 937-943.	2.6	15
140	Treatment of co-morbid cocaine dependence in schizophrenia with topiramate. <i>Schizophrenia Research</i> , 2010, 116, 97.	2.0	3
141	A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. <i>Drug and Alcohol Dependence</i> , 2010, 107, 188-195.	3.2	36
142	Individualized smoking cessation treatment in an outpatient setting: Predictors of outcome in a sample with psychiatric and addictions co-morbidity. <i>Addictive Behaviors</i> , 2010, 35, 811-817.	3.0	25
143	Perspective: Translational Studies on Glutamate and Dopamine Neurocircuitry in Addictions: Implications for Addiction Treatment. <i>Neuropsychopharmacology</i> , 2009, 34, 255-256.	5.4	1
144	Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia. <i>Drug and Alcohol Dependence</i> , 2009, 104, 94-99.	3.2	58

#	ARTICLE	IF	CITATIONS
145	Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. <i>Schizophrenia Research</i> , 2009, 107, 332-333.	2.0	27
146	Risk/reward decision-making in schizophrenia: A preliminary examination of the influence of tobacco smoking and relationship to Wisconsin Card Sorting Task performance. <i>Schizophrenia Research</i> , 2009, 110, 156-164.	2.0	48
147	Prepulse inhibition deficits in schizophrenia are modified by smoking status. <i>Schizophrenia Research</i> , 2009, 112, 86-90.	2.0	34
148	Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: Effects of smoking status. <i>Schizophrenia Research</i> , 2009, 114, 91-97.	2.0	36
149	Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: A preliminary study. <i>Schizophrenia Research</i> , 2009, 115, 317-324.	2.0	29
150	Mecamylamine – a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2709-2721.	1.8	85
151	Exploiting Nicotinic Receptor Mechanisms for the Treatment of Schizophrenia and Depression. <i>Journal of Dual Diagnosis</i> , 2009, 5, 159-167.	1.2	2
152	Effects of Topiramate on Smoking in Patients With Schizoaffective Disorder, Bipolar Type. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 193-194.	1.4	2
153	Predictors of Abstinence and Changes in Psychiatric Symptoms in a Pooled Sample of Smokers With Schizophrenia Receiving Combination Pharmacotherapy and Behavioral Therapy for Smoking Cessation. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 601-603.	1.4	13
154	Treatment of Tobacco Dependence in Mental Health and Addictive Disorders. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 368-378.	1.9	107
155	Mechanisms Underlying the Comorbidity of Tobacco Use in Mental Health and Addictive Disorders. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 356-367.	1.9	77
156	Addressing Tobacco Dependence in Psychiatric Practice: Promises and Pitfalls. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 353-355.	1.9	21
157	Treatment of comorbid tobacco use in people with serious mental illness. <i>Journal of Psychiatry and Neuroscience</i> , 2009, 34, E1-2.	2.4	17
158	Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia. <i>Schizophrenia Research</i> , 2008, 103, 326-327.	2.0	26
159	Effects of Acute Tobacco Abstinence in Adolescent Smokers Compared with Nonsmokers. <i>Journal of Adolescent Health</i> , 2008, 43, 46-54.	2.5	39
160	A Placebo-Controlled Trial of Bupropion Combined with Nicotine Patch for Smoking Cessation in Schizophrenia. <i>Biological Psychiatry</i> , 2008, 63, 1092-1096.	1.3	143
161	Neurocognitive Performance Among Alcohol Dependent Men With and Without Physical Violence Toward Their Partners: A Preliminary Report. <i>American Journal of Drug and Alcohol Abuse</i> , 2008, 34, 29-37.	2.1	36
162	Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. <i>Nicotine and Tobacco Research</i> , 2008, 10, 1691-1715.	2.6	616

#	ARTICLE	IF	CITATIONS
163	Survey of Clinician Attitudes Toward Smoking Cessation for Psychiatric and Substance Abusing Clients. <i>Journal of Addictive Diseases</i> , 2008, 27, 55-63.	1.3	29
164	Effects of Topiramate on Smoking in Patients With Schizoaffective Disorder, Bipolar Type. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 247-248.	1.4	12
165	Nicotinic Antagonist Augmentation of Selective Serotonin Reuptake Inhibitor-Refractory Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 340-344.	1.4	119
166	A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 584-587.	1.4	44
167	Transcranial Magnetic Stimulation to Understand the Pathophysiology and Treatment of Substance Use Disorders. <i>Current Drug Abuse Reviews</i> , 2008, 1, 328-339.	3.4	44
168	Adverse Childhood Experiences, Smoking and Mental Illness in Adulthood: A Preliminary Study. <i>Annals of Clinical Psychiatry</i> , 2007, 19, 89-97.	0.6	26
169	Alcohol use and misuse. <i>Cmaj</i> , 2007, 176, 621-622.	2.0	8
170	Comparing gain- and loss-framed messages for smoking cessation with sustained-release bupropion: A randomized controlled trial.. <i>Psychology of Addictive Behaviors</i> , 2007, 21, 534-544.	2.1	128
171	Neurobiological Links Between Nicotine Addiction and Schizophrenia. <i>Journal of Dual Diagnosis</i> , 2007, 3, 27-42.	1.2	26
172	Age of onset of smoking among alcohol dependent men attending substance abuse treatment after a domestic violence arrest. <i>Addictive Behaviors</i> , 2007, 32, 2020-2031.	3.0	2
173	Reliability of the Fagerstr�m Test for Nicotine Dependence, Minnesota Nicotine Withdrawal Scale, and Tiffany Questionnaire for Smoking Urges in Smokers with and without Schizophrenia. <i>Drug and Alcohol Dependence</i> , 2007, 86, 278-282.	3.2	110
174	Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia. <i>Schizophrenia Research</i> , 2007, 91, 217-225.	2.0	48
175	Cigarette smoking in Chinese male inpatients with schizophrenia: A cross-sectional analysis. <i>Journal of Psychiatric Research</i> , 2007, 41, 43-48.	3.1	35
176	Neuropsychological deficits in nonsmokers with schizophrenia: Effects of a nicotinic antagonist. <i>Schizophrenia Research</i> , 2006, 85, 213-221.	2.0	23
177	A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: Involvement of nicotinic receptor mechanisms. <i>Schizophrenia Research</i> , 2006, 87, 307-315.	2.0	97
178	Treatment of patients with substance use disorders, second edition. American Psychiatric Association. <i>American Journal of Psychiatry</i> , 2006, 163, 5-82.	7.2	62
179	Co-Morbidity of Smoking in Patients with Psychiatric and Substance Use Disorders. <i>American Journal on Addictions</i> , 2005, 14, 106-123.	1.4	518
180	Effects of Cigarette Smoking on Spatial Working Memory and Attentional Deficits in Schizophrenia. <i>Archives of General Psychiatry</i> , 2005, 62, 649.	12.3	319

#	ARTICLE	IF	CITATIONS
181	Smoking cue reactivity in schizophrenia: Effects of a nicotinic receptor antagonist. <i>Biological Psychiatry</i> , 2005, 57, 802-808.	1.3	28
182	Daily patterns of alcohol, cigarette, and marijuana use in adolescent smokers and nonsmokers. <i>Addictive Behaviors</i> , 2005, 30, 271-283.	3.0	49
183	Non-nicotine pharmacotherapies for nicotine dependence. <i>Essential Psychopharmacology</i> , 2005, 6, 158-72.	0.9	7
184	Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. <i>Journal of Psychopharmacology</i> , 2004, 18, 457-474.	4.0	191
185	Noradrenergic $\alpha$ -2 agonists have anxiolytic-like actions on stress-related behavior and mesoprefrontal dopamine biochemistry. <i>Brain Research</i> , 2004, 1027, 173-178.	2.2	22
186	Characteristics of Tobacco-Smoking Problem Gamblers Calling a Gambling Helpline. <i>American Journal on Addictions</i> , 2004, 13, 471-493.	1.4	54
187	Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. <i>Schizophrenia Research</i> , 2004, 70, 263-275.	2.0	66
188	Current pharmacological treatments for nicotine dependence. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 42-48.	8.7	151
189	Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. <i>Journal of Psychopharmacology</i> , 2004, 18, 457-474.	4.0	202
190	Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. <i>Addiction</i> , 2003, 98, 1625-1632.	3.3	119
191	A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. <i>Biological Psychiatry</i> , 2003, 53, 136-143.	1.3	98
192	A placebo controlled trial of bupropion for smoking cessation in schizophrenia. <i>Biological Psychiatry</i> , 2002, 52, 53-61.	1.3	296
193	The potential of dopamine agonists in drug addiction. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 491-499.	4.1	61
194	Effects of Smoking Abstinence on Visuospatial Working Memory Function in Schizophrenia. <i>Neuropsychopharmacology</i> , 2002, 26, 75-85.	5.4	201
195	Response to Sherry Leonard and Laura Giordano's Letter. <i>Neuropsychopharmacology</i> , 2002, 27, 1084-1085.	5.4	0
196	Treating Tobacco Addiction in Schizophrenia: Where do we go From Here?. <i>Addiction</i> , 2002, 97, 795-796.	3.3	7
197	The Neurobiology of Opioid Dependence: Implications for Treatment. <i>Science &amp; Practice Perspectives / A Publication of the National Institute on Drug Abuse</i> , National Institutes of Health, 2002, 1, 13-20.	0.4	326
198	Effects of nicotine pretreatment on dopaminergic and behavioral responses to conditioned fear stress in rats: dissociation of biochemical and behavioral effects. <i>Biological Psychiatry</i> , 2001, 49, 300-306.	1.3	16

#	ARTICLE	IF	CITATIONS
199	Comorbidity of psychiatric and substance abuse disorders. <i>Current Opinion in Psychiatry</i> , 2000, 13, 327-331.	6.3	98
200	Gender Differences in Learned Helplessness Behavior Are Influenced by Genetic Background. <i>Pharmacology Biochemistry and Behavior</i> , 2000, 66, 811-817.	2.9	65
201	Nicotine Transdermal Patch and Atypical Antipsychotic Medications for Smoking Cessation in Schizophrenia. <i>American Journal of Psychiatry</i> , 2000, 157, 1835-1842.	7.2	353
202	Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. <i>Biological Psychiatry</i> , 2000, 47, 1080-1086.	1.3	159
203	Effects of repeated nicotine pre-treatment on mesoprefrontal dopaminergic and behavioral responses to acute footshock stress. <i>Brain Research</i> , 1998, 801, 36-49.	2.2	37
204	Possible serotonin syndrome with trazodone addition to fluoxetine. <i>Biological Psychiatry</i> , 1996, 39, 384-385.	1.3	24
205	Rate of recovery of D1 and D2 dopaminergic receptors in young vs. adult rat striatal tissue following alkylation with ethoxycarbonyl-ethoxy-dihydroquinoline (EEDQ). <i>Developmental Brain Research</i> , 1992, 66, 286-289.	1.7	16
206	Evaluating Treatment Mechanisms of Varenicline: Mediation by Affect and Craving. <i>Nicotine and Tobacco Research</i> , 0, , .	2.6	1